Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Equity Ratio (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Equity Ratio for 5 consecutive years, with 0.81 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 7.25% to 0.81 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.81, a 7.25% increase, with the full-year FY2025 number at 0.66, changed N/A from a year prior.
  • Equity Ratio was 0.81 for Q4 2025 at Neuphoria Therapeutics, up from 0.46 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.87 in Q2 2022 to a low of 0.46 in Q3 2025.
  • A 4-year average of 0.74 and a median of 0.76 in 2023 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 7.25% in 2025; the steepest drop was 38.58% in 2025.
  • Neuphoria Therapeutics' Equity Ratio stood at 0.87 in 2022, then decreased by 11.55% to 0.77 in 2023, then dropped by 1.83% to 0.76 in 2024, then grew by 7.25% to 0.81 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Equity Ratio are 0.81 (Q4 2025), 0.46 (Q3 2025), and 0.66 (Q2 2025).